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Antibody detection and identification are processes that are 
commonly performed in the transfusion service before transfusion 
of allogeneic red blood cells (RBCs). Antibody identification 
usually follows the discovery of a positive antibody detection 
test, or other factors such as ABO serum/cell discrepancy or an 
incompatible crossmatch. Antibody identification is a necessary 
practice in blood banking to determine the suitability of blood 
products for transfusion on an individual basis. When the presence 
of multiple antibodies is suspected, several methods, including 
neutralization of patient’s plasma, titration, elution, chemical 
or enzyme treatment of reagent RBCs, and adsorption with 
allogeneic RBCs, may be used to separate and properly identify 
other atypical antibodies that are present in a single serum or 
plasma sample. This review will focus on the use of allogeneic 
adsorption to identify antibody specificities in a patient’s sample. 
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Principle
Antibody detection and identification are processes that 
are commonly performed in the transfusion service before 
the transfusion of allogeneic red blood cells (RBCs). Antibody 
identification usually follows the discovery of a positive 
antibody detection test, or other factors such as ABO serum/
cell discrepancy or incompatible crossmatch.1 Antibody 
identification is a necessary practice in blood banking to 
determine blood products that are suitable for transfusion to 
an individual. Routinely, antibody identification practices in a 
blood bank comprise the testing of a patient’s plasma against 
reagent RBCs using standard agglutination and indirect 
antiglobulin methods.1 There are, however, instances when 
identification of multiple antibodies may be complicated and 
require additional serologic methods. When the presence of 
multiple antibodies is suspected, several methods—including 
neutralization of patient’s plasma, titration, elution, chemical 
or enzyme treatment of reagent RBCs, and adsorption with 
allogeneic RBCs—may be used to separate and properly 
identify antibodies that are present in a single serum or 
plasma sample.
Performing pretransfusion testing with a plasma or 
serum sample that contains multiple antibodies can present 
serologic challenges. Differentiating and properly identifying 
antibody specificities that are present in a sample containing 
multiple antibodies can be achieved by adsorption of patient 
plasma or serum with allogeneic RBCs. Allogeneic adsorption 
is used in blood banking to remove and/or separate antibody 
specificities from a plasma or serum sample with the use of 
RBCs that express the corresponding antigen and that are 
antigen-negative for other antibodies.2
If the patient’s phenotype is known, adsorptions with 
allogeneic RBCs that are phenotypically similar to the patient’s 
RBCs may be used. This process must ensure that adsorption 
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• Select test RBCs to be used for allogeneic adsorption.
• Wash the test RBCs three to four times with phosphate-buffered 
saline.
• Remove all supernatant saline from the washed RBCs.
• If enzyme treatment is desired, follow manufacturer’s directions and 
treat the RBCs.
• Wash the RBCs three to four times after treatment with enzymes.
• Add 1 volume serum or plasma to 1 volume washed, packed RBCs.
• Stopper, gently mix well, and incubate for 30–60 minutes at 37°C. 
• Centrifuge for 5 minutes and remove the plasma/serum. Test 
against fresh sample of adsorbing cells to see if adsorption is 
complete.
• Repeat the procedure with fresh adsorbing cells if adsorption is 
incomplete.
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cannot remove any antibody(ies) that the patient may form 
based on his or her RBC phenotype. For example, if the patient 
types as C–, E–, K–, Fy(a–), Fy(b–), Jk(b–), and S–, the 
adsorbing cells must be negative for these antigens so that, 
if present, antibodies to these antigens will not be adsorbed 
onto the adsorbing cells. It is important to note, however, that 
the use of phenotypically similar cells for adsorption carries 
the inherent risk of adsorbing out alloantibodies to variant 
antigens. This method should be used with extreme caution.
A preferred method is the use of differential adsorptions 
using a set of three different adsorbing cells with known 
phenotypes. Generally, one cell should be R1R1, another should 
be R2R2, and the third cell should be rr. Treating the RBCs to 
be used for allogeneic adsorption with proteolytic enzymes 
can also be performed to enhance the adsorption process. 
Treatment with enzymes will destroy certain antigens that are 
sensitive to enzyme treatment such as antigens in the Duffy 
and MNS blood group systems.
Application
Adsorption with allogeneic RBCs presents antibody(ies) 
to the corresponding antigen-positive RBCs under optimal 
conditions so that the antibody will attach to the antigen, 
thereby removing the antibody from the serum or plasma.3 
Allogeneic adsorption methods can be used to confirm an 
antibody specificity, separate multiple antibodies present in 
a single plasma or serum, remove autoantibody to permit 
the detection of underlying alloantibodies, remove unwanted 
antibody from serum that is suitable for the preparation of 
typing reagents, and assist in detecting the presence of weak 
antigens on RBCs.4
When all or most cells of an antibody panel react at 
different strengths or different phases in conjunction with a 
negative autocontrol, the presence of multiple antibodies in the 
patient’s plasma or serum should be suspected, especially if 
the reactivity does not fit a single antibody using inclusion and 
exclusion methods.1,5 It is important to exclude the presence of a 
possible single antibody to a high-prevalence antigen that may 
be showing dosage on an RBC panel. If the patient’s phenotype 
is known or can be obtained, perform testing using a selected 
cell panel that is similar to the patient’s phenotype. Several 
selected cell panels may be necessary to resolve the antibody 
identification issue. There are instances where the separation 
and identification of multiple antibodies cannot be attained 
using the methods described here because of insufficient 
reagent RBCs to exclude or include all common alloantibodies. 
In this instance, other methods such as adsorption of known 
antibodies with allogeneic RBCs can be performed, and the 
adsorbed plasma can then be used for the identification of 
other antibodies.
In the presence of multiple antibodies in a single plasma 
or serum sample, allogeneic adsorptions are used to confirm or 
exclude suspected antibodies against RBC antigens that may 
be masked by an antibody of known specificity. For example, 
if the RBCs of a patient type as E– and the patient’s serum 
contains anti-U, it will be statistically difficult to find sufficient 
U–E+ RBC samples to confirm or exclude the presence of 
anti-E. In this scenario, the use of allogeneic adsorptions will 
be necessary to remove anti-U from the test plasma or serum, 
leaving the adsorbed plasma with anti-E, if present. The 
adsorbed plasma can then be tested against E+U+ and E–U+ 
cells to determine if the patient’s plasma contains anti-E.
If there is no known antibody specificity in the patient’s 
plasma, differential adsorptions may be necessary to exclude 
or include all the common RBC antigens.
Procedure
Select group O allogeneic RBCs to be used for adsorption 
that are positive for the antigen against which the antibody 
to be removed is directed (for plasma with known antibody 
specificity) and negative for the other antibodies that are 
suspected to be present in a single plasma or serum sample. 
When there is no known antibody specificity in the test plasma 
and the patient’s phenotype is known, select group O allogeneic 
RBCs that are phenotypically similar to the patient’s RBCs. 
Note that the use of phenotypically similar cells for adsorption 
carries the inherent risk of adsorbing out alloantibodies to 
variant antigens and should be used with extreme caution. 
For patients with unknown phenotypes, select a set of three 
different RBCs with known phenotypes. The group O RBCs 
selected should be R1R1, R2R2, and rr. One of the cells must be 
negative for K, another negative for Jka, and the third negative 
for Jkb to ensure that alloantibodies to common RBC antigens 
will be excluded.6 Adsorption can be performed with RBCs 
that are untreated or treated with proteolytic enzymes. If 
adsorption is performed with untreated RBCs, one of the cells 
selected should be negative for S and Fya or Fyb.7
Obtain an aliquot of the selected RBCs and wash at least 
three times with saline. After the last wash, centrifuge the 
RBCs for 5 minutes and remove the supernatant saline using 
disposable pipettes. Add 1 volume of washed, packed RBCs 
to 1 volume of the patient’s plasma or serum and mix gently. 
Incubate at 37°C for 30–60 minutes. Mix the serum or plasma/
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cell mixture periodically throughout the incubation period to 
enhance adsorption.8
After the incubation period has elapsed, centrifuge the 
serum or plasma/cell mixture for 5 minutes to pack the RBCs. 
Remove the supernatant fluid (adsorbed plasma) with a 
disposable pipette and dispense into a clean, properly marked 
test tube. Discard the RBCs if an eluate will not be prepared. 
If an elution study is indicated, save the RBCs. An elution 
study can be performed using the first adsorbing cell, or sets of 
adsorbing cells, to determine the antibody specificity that has 
been removed by adsorption. Test an aliquot of the adsorbed 
plasma or serum with an aliquot of fresh adsorbing cells to see 
if adsorption is complete. This testing should be performed by 
the same method that will be used to test the reagent panel 
cells with the adsorbed plasma. For example, if the adsorbed 
plasma/reagent cell mixture will be enhanced by low-ionic-
strength saline (LISS) or polyethylene glycol (PEG), the same 
method should be used for testing of the adsorbed plasma with 
adsorbing cells. If adsorption is complete, no reactivity will be 
observed. If reactivity is observed, adsorption is incomplete. 
For incomplete adsorption, repeat the process using a fresh 
volume of washed, packed RBCs until complete adsorption 
is attained. Once complete adsorption is observed, test the 
adsorbed plasma with a panel of reagent RBCs to exclude other 
underlying alloantibodies.
It is important to know which antibody specificities may be 
present in each adsorbed plasma. R1R1 allogeneic RBCs adsorb 
anti-D, -C, and -e and other antibodies to high-prevalence 
antigens. Specificities left behind are anti-c and -E. R2R2 
allogeneic RBCs adsorb anti-D, -c, and -E and other antibodies 
to high-prevalence antigens. Specificities left behind are anti-C 
and -e. The rr cells adsorb anti-c and -e and antibodies to high-
prevalence antigens. Specificities left behind are anti-D, -C, and 
-E. In addition to these antibodies, alloantibodies detecting 
antigens that are absent from the adsorbing cells will also be 
left behind in the adsorbed plasma. The adsorbed plasma can 
be tested with or without enhancements such as LISS or PEG.
It is vital to note that adsorption is more effective if the area 
of contact between the plasma or serum and RBCs is large. 
This effect can be obtained by using large-bore test tubes (16 × 
100 mm) for adsorption.9 To completely remove an unwanted 
antibody, it may be necessary to perform multiple adsorptions, 
although there is an increased risk of diluting the serum with 
each successive adsorption, which can lead to weak or false-
negative reactions. The number of adsorptions necessary to 
completely remove an unwanted antibody can be suggestively 
determined by the strength of reactivity on the initial antibody 
panel. Theoretically, the total adsorptions needed to completely 
remove an unwanted antibody is the strength of reactivity on 
the initial panel plus one. For example, if the initial panel’s 
reactivity is 3+, perform four adsorptions.10 Repeat adsorptions 
should always be performed with a fresh volume of RBCs and 
not the RBCs already used for prior adsorptions.
Pretreating the RBCs used for allogeneic adsorptions with 
proteolytic enzymes will reduce the number of adsorptions 
needed for complete removal of unwanted antibodies because 
enzyme treatment of cells enhances the uptake of antibodies 
against enzyme-resistant antigens. The use of a higher cell-to-
serum ratio can help the adsorption process by increasing the 
amount of antigens able to adsorb the target antibody.6
Limitations
Adsorption with allogeneic RBCs does not only remove 
targeted antibodies but also removes antibodies to high-
prevalence antigens when they are present in the test plasma 
or serum. RBCs used for allogeneic adsorptions are presumed 
to be positive for all high-prevalence antigens. If the test 
plasma or serum happens to contain an antibody to any of the 
high-prevalence antigens, that antibody will be adsorbed onto 
the RBCs. In this case, the antibody will not be detected in the 
adsorbed plasma but can be recovered in an eluate prepared 
from the adsorbing cells.
Adsorption with allogeneic RBCs is a time-consuming 
process that may take several hours to complete if multiple 
adsorptions are required, and this step may be contraindicated 
for a patient who is in critical need of blood transfusion. When 
allogeneic adsorption is indicated for such a patient, transfusion 
of phenotype-matched units may be necessary while testing is 
in process.
Adsorptions pose the risk of diluting the adsorbed plasma, 
thereby weakening the strength of antibody(ies) present. 
Weak-reacting antibodies may be completely missed when 
testing adsorbed plasma. To attenuate the possibility of missing 
a weak-reacting antibody in an allogeneic adsorbed plasma, 
the number of adsorptions should be limited to a maximum of 
six. Increasing the ratio of adsorbed plasma to reagent RBCs 
during the testing phase increases the chances of identifying 
weak-reacting alloantibodies.
Quality Control
To ensure that allogeneic adsorption is complete, test the 
adsorbed plasma with a freshly prepared, untreated, 3–5 
158 IMMUNOHEMATOLOGY, Volume 33, Number 4, 2017
percent suspension of allogeneic RBCs used for adsorption 
with or without enhancement. If reactivity persists, adsorption 
is not complete. A negative result proves that adsorption is 
complete, and the adsorbed plasma can be used for testing with 
RBC panels. However, it is important to note the phenotype 
of the adsorbing cells when testing for completeness. If anti-
Jka, for example, is present in the plasma, adsorption with 
allogenic cells that are Jk(a–) will not remove this antibody 
from the plasma, and the adsorbed plasma will not react with 
the untreated cells that are Jk(a–).
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